HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)
China · Delayed Price · Currency is CNY 3.430
+0.070 (2.08%)
Feb 3, 2026, 3:04 PM CST
SHE:002437 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,243 | 2,436 | 2,619 | 3,103 | 3,131 | 3,038 |
Other Revenue | 5.02 | 5.02 | 7.02 | 5.09 | 14.07 | 17.26 |
| 2,248 | 2,441 | 2,626 | 3,108 | 3,145 | 3,055 | |
Revenue Growth (YoY) | -7.54% | -7.06% | -15.51% | -1.19% | 2.96% | -39.55% |
Cost of Revenue | 1,161 | 1,137 | 1,096 | 1,362 | 832.93 | 850.49 |
Gross Profit | 1,087 | 1,303 | 1,530 | 1,746 | 2,312 | 2,204 |
Selling, General & Admin | 714.88 | 959.35 | 1,244 | 1,518 | 2,058 | 2,178 |
Research & Development | 91.75 | 90.79 | 85.44 | 100.63 | 97.73 | 125.49 |
Other Operating Expenses | 76.38 | 28.28 | 29.22 | 41.52 | 41.17 | 38.43 |
Operating Expenses | 883.81 | 1,078 | 1,358 | 1,660 | 2,197 | 2,349 |
Operating Income | 203.31 | 225.32 | 171.96 | 85.61 | 115.68 | -144.7 |
Interest Expense | -2.88 | -9.82 | -42.65 | -68.67 | -71.48 | -88.55 |
Interest & Investment Income | 5.06 | 15.21 | 18.47 | 20.78 | 17.21 | 815.05 |
Currency Exchange Gain (Loss) | 1.13 | 1.13 | 1.19 | 13.54 | -3.86 | -11.85 |
Other Non Operating Income (Expenses) | 1.13 | 0.81 | -6.47 | -4.19 | -14.1 | -3.09 |
EBT Excluding Unusual Items | 207.75 | 232.66 | 142.49 | 47.08 | 43.44 | 566.86 |
Impairment of Goodwill | - | - | - | -42.13 | - | - |
Gain (Loss) on Sale of Investments | 28.25 | -13.98 | -41.37 | -269.57 | -9.31 | 11.47 |
Gain (Loss) on Sale of Assets | 5.26 | 3.4 | 2.84 | 3.82 | 4.65 | -40.67 |
Asset Writedown | -3.88 | -3.53 | -0.28 | -37.32 | -1.84 | -22.76 |
Other Unusual Items | 93.59 | 65.15 | 71.08 | 27.44 | 49.03 | 50.23 |
Pretax Income | 330.97 | 283.69 | 176.78 | -269.68 | 85.97 | 565.12 |
Income Tax Expense | 32.29 | 41.15 | 48.08 | 19.84 | 32.14 | 156.44 |
Earnings From Continuing Operations | 298.68 | 242.54 | 128.7 | -289.52 | 53.84 | 408.68 |
Minority Interest in Earnings | -5.64 | -9.78 | -8.37 | -1.81 | -8.8 | -8.63 |
Net Income | 293.04 | 232.76 | 120.33 | -291.33 | 45.04 | 400.05 |
Net Income to Common | 293.04 | 232.76 | 120.33 | -291.33 | 45.04 | 400.05 |
Net Income Growth | 265.40% | 93.43% | - | - | -88.74% | - |
Shares Outstanding (Basic) | 2,195 | 2,198 | 2,200 | 2,199 | 2,197 | 2,198 |
Shares Outstanding (Diluted) | 2,302 | 2,262 | 2,200 | 2,199 | 2,197 | 2,198 |
Shares Change (YoY) | 4.69% | 2.82% | 0.05% | 0.07% | -0.04% | -0.01% |
EPS (Basic) | 0.13 | 0.11 | 0.05 | -0.13 | 0.02 | 0.18 |
EPS (Diluted) | 0.13 | 0.10 | 0.05 | -0.13 | 0.02 | 0.18 |
EPS Growth | 249.02% | 88.12% | - | - | -88.74% | - |
Free Cash Flow | 371.98 | 348.04 | 244.55 | 228.6 | 239.67 | -30.9 |
Free Cash Flow Per Share | 0.16 | 0.15 | 0.11 | 0.10 | 0.11 | -0.01 |
Gross Margin | 48.35% | 53.40% | 58.27% | 56.17% | 73.52% | 72.16% |
Operating Margin | 9.04% | 9.23% | 6.55% | 2.76% | 3.68% | -4.74% |
Profit Margin | 13.03% | 9.54% | 4.58% | -9.37% | 1.43% | 13.10% |
Free Cash Flow Margin | 16.55% | 14.26% | 9.31% | 7.36% | 7.62% | -1.01% |
EBITDA | - | 328.9 | 275.53 | 215.66 | 254.64 | 4.47 |
EBITDA Margin | - | 13.48% | 10.49% | 6.94% | 8.10% | 0.15% |
D&A For EBITDA | - | 103.57 | 103.57 | 130.05 | 138.96 | 149.16 |
EBIT | 203.31 | 225.32 | 171.96 | 85.61 | 115.68 | -144.7 |
EBIT Margin | 9.04% | 9.23% | 6.55% | 2.76% | 3.68% | -4.74% |
Effective Tax Rate | 9.76% | 14.51% | 27.20% | - | 37.38% | 27.68% |
Revenue as Reported | 2,248 | 2,441 | 2,626 | 3,108 | 3,145 | 3,055 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.